全文获取类型
收费全文 | 1802篇 |
免费 | 137篇 |
国内免费 | 24篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 46篇 |
妇产科学 | 26篇 |
基础医学 | 234篇 |
口腔科学 | 34篇 |
临床医学 | 275篇 |
内科学 | 341篇 |
皮肤病学 | 34篇 |
神经病学 | 112篇 |
特种医学 | 293篇 |
外科学 | 162篇 |
综合类 | 32篇 |
预防医学 | 119篇 |
眼科学 | 48篇 |
药学 | 85篇 |
中国医学 | 1篇 |
肿瘤学 | 106篇 |
出版年
2023年 | 8篇 |
2022年 | 9篇 |
2021年 | 29篇 |
2020年 | 14篇 |
2019年 | 10篇 |
2018年 | 26篇 |
2017年 | 24篇 |
2016年 | 31篇 |
2015年 | 22篇 |
2014年 | 52篇 |
2013年 | 64篇 |
2012年 | 61篇 |
2011年 | 62篇 |
2010年 | 65篇 |
2009年 | 72篇 |
2008年 | 75篇 |
2007年 | 69篇 |
2006年 | 66篇 |
2005年 | 56篇 |
2004年 | 40篇 |
2003年 | 57篇 |
2002年 | 52篇 |
2001年 | 49篇 |
2000年 | 51篇 |
1999年 | 39篇 |
1998年 | 63篇 |
1997年 | 55篇 |
1996年 | 55篇 |
1995年 | 47篇 |
1994年 | 34篇 |
1993年 | 29篇 |
1992年 | 30篇 |
1991年 | 37篇 |
1990年 | 26篇 |
1989年 | 53篇 |
1988年 | 42篇 |
1987年 | 38篇 |
1986年 | 31篇 |
1985年 | 36篇 |
1984年 | 21篇 |
1983年 | 35篇 |
1982年 | 32篇 |
1981年 | 25篇 |
1980年 | 24篇 |
1979年 | 17篇 |
1978年 | 21篇 |
1977年 | 23篇 |
1976年 | 14篇 |
1975年 | 12篇 |
1974年 | 12篇 |
排序方式: 共有1963条查询结果,搜索用时 15 毫秒
81.
Ralf Gutzmer Jürgen C. Becker Alexander Enk Claus Garbe Axel Hauschild Martin Leverkus Georg Reimer Regina Treudler Athanasios Tsianakas Claas Ulrich Andreas Wollenberg Bernhard Homey 《Journal der Deutschen Dermatologischen Gesellschaft》2011,9(3):195-202
Inhibitors of the epidermal growth factor receptor (EGFR) are increasingly used in the treatment of various entities of malignant tumors. Patients treated with EGFR inhibitors very likely develop cutaneous side effects. The development of a papulopustular, follicular exanthema during the first weeks of therapy correlates with therapeutic benefit. However, this exanthema and other cutaneous side effects can impair the quality of life of the patient and might limit the therapy with the EGFR inhibitor. For an optimal therapeutic benefit and quality of life an adequate management of cutaneous side effects is necessary. A panel of German dermatologists developed on the basis of personal experience and current literature consensus recommendations for the management of cutaneous side effects of EGFR inhibitors. 相似文献
82.
Marianne Brodmann Martin Werner Dirk-Roelfs Meyer Peter Reimer Karsten Krüger Juan F. Granada Michael R. Jaff Henrik Schroeder 《JACC: Cardiovascular Interventions》2018,11(23):2357-2364
Objectives
The aim of this study was to assess the safety and effectiveness of a next-generation low-dose drug-coated balloon (DCB) designed to optimize the amount of drug transferred into the vessel wall and to maximize the amount of time the drug resides in the vessel wall.Background
Several randomized controlled studies evaluating various DCBs have demonstrated a significantly higher patency rate compared with noncoated percutaneous transluminal angioplasty balloons at 1 year. However, the data are limited and vary by DCB at longer follow-up time points. An earlier generation low-dose DCB failed to demonstrate significant treatment effect at 2 years, raising questions regarding the durability of low-dose DCBs.Methods
In this prospective, multicenter trial, 294 patients were randomized (3:1) to treatment with a DCB or an uncoated percutaneous transluminal angioplasty balloon. Assessments at 2 years included primary patency with duplex ultrasonography, clinically driven target lesion revascularization, and functional outcomes.Results
Primary patency at 2 years was significantly higher in the DCB cohort (75.9% vs. 61.0%; p = 0.025), and the rate of clinically driven target lesion revascularization was significantly lower (12.1% vs. 30.5%; p < 0.001). There were no major limb amputations in either group. The rates of all-cause (6.5% vs. 5.1%; p = 1.00) and cardiovascular-related (1.6% vs. 1.7%; p = 1.00) mortality were similar between groups. Functional improvements over baseline were sustained in both groups, with 60% fewer reinterventions in the DCB group.Conclusions
A sustained treatment effect is achievable with a low-dose DCB with an optimized coating formulation. This trial demonstrated for the first time a statistically significantly higher primary patency rate for a low-dose DCB versus PTA at 2 years. (CVI Drug Coated Balloon European Randomized Clinical Trial; NCT01858363) 相似文献83.
Schneider G Reimer P Mamann A Kirchin MA Morana G Grazioli L 《Topics in magnetic resonance imaging : TMRI》2005,16(1):107-124
Magnetic resonance imaging is an established imaging method for the evaluation of the abdomen. Accurate assessment of the liver, spleen, pancreas, bile ducts, vascular structures, and retroperitoneal organs (eg, the kidneys, the collecting system, and the adrenals) are possible on MR imaging. The intravenous administration of MR contrast agents can frequently improve the examination and provide more specific diagnoses. The advent of more specific, "hepatobiliary" contrast agents has further improved the differential diagnostic process, particularly for MR imaging of the liver. The availability of orally administered MR contrast agents has further extended the range of abdominal applications, making MR imaging of the small bowel and the colon established imaging procedures. 相似文献
84.
JK Gass SK Chan E Rytina DC Greenberg NP Burrows 《Journal of the European Academy of Dermatology and Venereology》2010,24(5):601-603
Background Merkel cell carcinoma (MCC) is a rare malignant cutaneous tumour, the incidence of which is increasing. Second malignancies have been reported to occur with high incidence in these patients. Objectives We report the rate and nature of multiple malignancies in patients with MCC treated over a 10 year period in Addenbrooke’s Hospital in Cambridge, United Kingdom, as well as the temporal relationship of these additional malignancies to the diagnosis of MCC. Results The 27 patients had an approximately equal sex incidence with a median age at diagnosis of 79 years. Seventy percent (n=19) of patients had a second primary malignant tumour; and 7 of these patients had two or more tumours in addition to the MCC. Eighteen patients had additional cutaneous malignancies: melanoma, squamous cell carcinoma and basal cell carcinoma, and 8 patients presented non‐cutaneous malignancy including colorectal, haematological and breast tumours. Of the 28 additional tumours in our patients, half were diagnosed prior to presentation of MCC, 32% within 6 months of diagnosis, and 18% between 6 months and 3 years after diagnosis. Possible reasons for the high rate of additional tumours in this population are discussed. Conclusions Our figures reflect a higher incidence of multiple malignancies in those with Merkel cell tumour than has previously been reported. This has important implications for the care and surveillance of these patients. 相似文献
85.
86.
87.
88.
89.
90.
DC Wilson MJ Cunningham MMcC Reid SS Johnston TF Fannin 《Acta paediatrica (Oslo, Norway : 1992)》1992,81(1):84-85
A baby with unilateral cleft lip, midline cleft palate and hypertelorism developed meningitis in the first 48 h of life. Examination of the nasopharynx showed a soft tissue mass, which was confirmed as a basal encephalocele by computed tomography. There was also congenital hydrocephalus and the corpus callosum was absent. Surgical treatment included repair of the anterior basal skull defect, repair of the lip and palate, and ventriculo-peritoneal shunt. There is currently evidence of developmental delay and right-sided visual impairment due to Morning Glory syndrome. This case demonstrates that basal encephalocele should be considered in any baby with midline facial deformity who develops meningitis. 相似文献